Epidiolex filed with FDA for Tuberous Sclerosis Complex.- GW Pharma
Related news and insights
GW Pharmaceuticals plc announced that the European Commission (EC) has approved the Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older.
GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for Epidyolex (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older.
GW Pharmaceuticals and Greenwich Biosciences announced that JAMA Neurology has published results of the company’s positive Phase III clinical trial of Epidiolex (cannabidiol) oral solution in seizures associated with tuberous sclerosis complex (TSC).